JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events-Reference-Cited by-同舟云学术

JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events

Published:2014-02-21 Issue:5 Volume:89 Page:517-523
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Alvarez-Larrán Alberto¹,Bellosillo Beatriz²,Pereira Arturo³,Kerguelen Ana⁴,Carlos Hernández-Boluda Juan⁵,Martínez-Avilés Luz²,Fernández-Rodríguez Concepción²,Gómez Montse⁵,Lombardía Luis⁶,Angona Anna¹,Ancochea Águeda¹,Senín Alicia¹,Longarón Raquel²,Navarro Blanca⁵,Collado María⁵,Besses Carlos¹

Affiliation:

1. Hematology Department; Hospital del Mar, Universitat Autònoma de Barcelona; Barcelona

2. Pathology Department; Hospital del Mar, Universitat Autònoma de Barcelona; Barcelona

3. Hemotherapy and Hemostasis Department; Hospital Clínic, Universitat de Barcelona; Barcelona

4. Hematology Department; Hospital La Paz; Madrid

5. Hematology and Medical Oncology Department; Hospital Clínico Universitario; Valencia

6. Molecular Laboratory; Centro Nacional de Investigaciones Oncológicas; Madrid

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23676/fullpdf

Reference34 articles.

1. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

2. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera;James;Nature,2005

3. A gain-of-function mutation of JAK2 in myeloproliferative disorders;Kralovics;New England J Med,2005

4. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis;Levine;Cancer Cell,2005

5. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel;Tefferi;Blood,2007

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature;British Journal of Haematology;2024-06-10

2. Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis;Annals of Hematology;2024-04-23

3. Interferons in the treatment of myeloproliferative neoplasms;Therapeutic Advances in Hematology;2024-01

4. SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera;Clinical Lymphoma Myeloma and Leukemia;2023-11

5. The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study;DAHUDER Medical Journal;2023-04-29